Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Survivors' knowledge of their diagnosis, treatment and possible late adverse effects after autologous stem cell transplantation for lymphoma.

Simensen VC, Smeland KB, Kiserud CE, Dahl AA, Bersvendsen HS, Fluge Ø, Fagerli UM, Fosså A.

Acta Oncol. 2019 Jul 9:1-8. doi: 10.1080/0284186X.2019.1637538. [Epub ahead of print]

PMID:
31286808
2.

Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes.

Bersvendsen HS, Haugnes HS, Fagerli UM, Fluge Ø, Holte H, Smeland KB, Wilsgaard T, Kiserud CE.

Acta Oncol. 2019 May;58(5):690-699. doi: 10.1080/0284186X.2018.1558370. Epub 2019 Jan 30.

PMID:
30696346
3.

Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity.

Smeland KB, Loge JH, Aass HCD, Aspelin T, Bersvendsen H, Bolstad N, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Holte H, Lund MB, Murbræch K, Reinertsen KV, Stenehjem JS, Kiserud CE.

Bone Marrow Transplant. 2019 Apr;54(4):607-610. doi: 10.1038/s41409-018-0342-y. Epub 2018 Sep 27. No abstract available.

PMID:
30262906
4.

Runaway Train: A Leaky Radiosensitive SCID with Skin Lesions and Multiple Lymphomas.

Fevang B, Fagerli UM, Sorte H, Aarset H, Hov H, Langmyr M, Keil TM, Bjørge E, Aukrust P, Stray-Pedersen A, Gedde-Dahl T.

Case Reports Immunol. 2018 May 14;2018:2053716. doi: 10.1155/2018/2053716. eCollection 2018.

5.

Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration.

Hjort MA, Hov H, Abdollahi P, Vandsemb EN, Fagerli UM, Lund B, Slørdahl TS, Børset M, Rø TB.

Exp Hematol Oncol. 2018 Apr 10;7:8. doi: 10.1186/s40164-018-0100-2. eCollection 2018.

6.

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, Laurell A, Räty R, Elonen E, Andersen NS, Brown PD, Kimby E, Bentzen H, Sundström C, Ehinger M, Karjalainen-Lindsberg ML, Delabie J, Ralfkiær E, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Kuittinen O, Niemann C, Geisler CH; Nordic Lymphoma Group.

Biol Blood Marrow Transplant. 2017 Mar;23(3):428-435. doi: 10.1016/j.bbmt.2016.12.634. Epub 2016 Dec 27.

7.

Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation.

Kiserud CE, Fagerli UM, Smeland KB, Fluge Ø, Bersvendsen H, Kvaløy S, Holte H, Dahl AA.

Acta Oncol. 2016 May;55(5):547-53. doi: 10.3109/0284186X.2015.1125015.

PMID:
27123741
8.

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H.

Br J Haematol. 2016 May;173(3):432-43. doi: 10.1111/bjh.13965. Epub 2016 Feb 23.

PMID:
26914167
9.

PET/MR brain imaging: evaluation of clinical UTE-based attenuation correction.

Aasheim LB, Karlberg A, Goa PE, Håberg A, Sørhaug S, Fagerli UM, Eikenes L.

Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1439-46. doi: 10.1007/s00259-015-3060-3. Epub 2015 Apr 22.

PMID:
25900276
10.

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.

Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H.

Haematologica. 2015 Jun;100(6):e240-3. doi: 10.3324/haematol.2014.119214. Epub 2015 Feb 14. No abstract available.

11.

Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.

Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Fosså A, Eriksson M, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, Fiirgaard B, Bersvendsen H, Fagerli UM.

Haematologica. 2015 Apr;100(4):534-40. doi: 10.3324/haematol.2014.108472. Epub 2014 Dec 5.

12.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, Pedersen LB, Loft A, Bogsrud TV, Kimby E, Hansen PB, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Lehmann AK, Sundstrom C, Karjalainen-Lindsberg ML, Ralfkiaer E, Ehinger M, Delabie J, Bentzen H, Schildt J, Kostova-Aherdan K, Frederiksen H, Brown Pde N, Geisler CH; Nordic Lymphoma Group.

Blood. 2014 May 8;123(19):2953-9. doi: 10.1182/blood-2013-12-541953. Epub 2014 Mar 20.

13.

High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008.

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H.

Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1704-9. doi: 10.4045/tidsskr.13.0243. English, Norwegian.

14.

HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase.

Rø TB, Holien T, Fagerli UM, Hov H, Misund K, Waage A, Sundan A, Holt RU, Børset M.

Exp Hematol. 2013 Jul;41(7):646-55. doi: 10.1016/j.exphem.2013.03.002. Epub 2013 Mar 14.

PMID:
23499762
15.

Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.

d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE.

J Clin Oncol. 2012 Sep 1;30(25):3093-9. doi: 10.1200/JCO.2011.40.2719. Epub 2012 Jul 30.

PMID:
22851556
16.

Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.

Wader KF, Fagerli UM, Børset M, Lydersen S, Hov H, Sundan A, Bofin A, Waage A.

Histopathology. 2012 Feb;60(3):443-51. doi: 10.1111/j.1365-2559.2011.04112.x.

PMID:
22276607
17.

Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.

Fagerli UM, Ullrich K, Stühmer T, Holien T, Köchert K, Holt RU, Bruland O, Chatterjee M, Nogai H, Lenz G, Shaughnessy JD Jr, Mathas S, Sundan A, Bargou RC, Dörken B, Børset M, Janz M.

Oncogene. 2011 Jul 14;30(28):3198-206. doi: 10.1038/onc.2011.79. Epub 2011 Apr 11.

PMID:
21478911
18.

Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters.

Wader KF, Fagerli UM, Holt RU, Børset M, Sundan A, Waage A.

Eur J Haematol. 2011 Nov;87(5):394-9. doi: 10.1111/j.1600-0609.2011.01622.x. Epub 2011 Aug 16.

PMID:
21466586
19.

High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.

Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H.

Br J Haematol. 2011 Mar;152(5):600-10. doi: 10.1111/j.1365-2141.2010.08519.x. Epub 2011 Jan 17. Review.

PMID:
21241276
20.

High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.

Brenne AT, Fagerli UM, Shaughnessy JD Jr, Våtsveen TK, Rø TB, Hella H, Zhan F, Barlogie B, Sundan A, Børset M, Waage A.

Eur J Haematol. 2009 May;82(5):354-63. doi: 10.1111/j.1600-0609.2009.01225.x. Epub 2009 Jan 13.

21.

c-Met signaling promotes IL-6-induced myeloma cell proliferation.

Hov H, Tian E, Holien T, Holt RU, Våtsveen TK, Fagerli UM, Waage A, Børset M, Sundan A.

Eur J Haematol. 2009 Apr;82(4):277-87. doi: 10.1111/j.1600-0609.2009.01212.x. Epub 2009 Jan 6.

22.

Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.

Wader KF, Fagerli UM, Holt RU, Stordal B, Børset M, Sundan A, Waage A.

Eur J Haematol. 2008 Nov;81(5):380-3. doi: 10.1111/j.1600-0609.2008.01130.x. Epub 2008 Aug 6.

23.

Hepatocyte growth factor promotes migration of human myeloma cells.

Holt RU, Fagerli UM, Baykov V, Rø TB, Hov H, Waage A, Sundan A, Børset M.

Haematologica. 2008 Apr;93(4):619-22. doi: 10.3324/haematol.11867. Epub 2008 Mar 6.

24.

Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.

Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD Jr, Sundan A, Børset M.

Blood. 2008 Jan 15;111(2):806-15. Epub 2007 Oct 12.

25.

HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A.

Blood. 2007 Apr 1;109(7):3024-30.

26.

A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.

Hov H, Holt RU, Rø TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Børset M.

Clin Cancer Res. 2004 Oct 1;10(19):6686-94.

27.

A nurse with a rash on her neck.

Aarset H, Fagerli UM, Opsjøn SL, Skarsvåg S.

Lancet. 1998 Aug 15;352(9127):540. No abstract available.

PMID:
9716059
28.

[Injuries in handball players].

Fagerli UM, Lereim I, Sahlin Y.

Tidsskr Nor Laegeforen. 1990 Feb 10;110(4):475-8. Norwegian.

PMID:
2309195

Supplemental Content

Loading ...
Support Center